Potential for Glembatumumab Vedotin in TNBC
December 9th 2016Linda T. Vahdat, MD, PhD, Breast Cancer Research Program Leader at Meyer Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian, discusses the ongoing METRIC trial and the potential for glembatumumab vedotin as a treatment for patients with triple-negative breast cancer (TNBC).
Read More
HER2-Enriched Subtype Strong Predictor of Response to Dual HER2 Blockade
December 9th 2016The <em>HER2</em>-enriched subtype of HER2-positive breast cancer is a strong predictor of sensitivity to dual HER2 blockade without the use of chemotherapy, according to findings presented at the 2016 San Antonio Breast Cancer Symposium.
Read More
Hormonal Therapy Improved PFS When Added to Dual HER2-Targeted Therapy
December 9th 2016The addition of an aromatase inhibitor (AI) to pertuzumab (Perjeta) and trastuzumab (Herceptin) improved progression-free survival (PFS) by 3.09 months, when compared with trastuzumab plus an AI, according to findings from the phase II PERTAIN trial.
Read More
Results Mixed for Veliparib Regimen in BRCA+ Breast Cancer
December 8th 2016The addition of the veliparib to carboplatin/paclitaxel demonstrated promising objective response rates and trends toward improvements in progression-free survival and overall survival in patients with advanced <em>BRCA</em>-positive breast cancer.
Read More
Longer Letrozole Treatment Shows Limited Benefit in Early Breast Cancer
December 8th 2016Extending treatment with letrozole by an additional 5 years after 5 years of successful treatment did not improve disease-free survival or overall survival in postmenopausal women with early-stage hormone receptor -positive breast cancer.
Read More
Everolimus/Fulvestrant Combo Improves PFS in HR+ Breast Cancer
December 8th 2016Adding everolimus to fulvestrant reduced the risk of progression or death by 40% compared with fulvestrant alone for postmenopausal patients with metastatic HR-positive, HER2-negative breast cancer who are resistant to aromatase inhibitor therapy.
Read More
Margetuximab Plus Chemotherapy in HER2+ Breast Cancer
December 8th 2016Mark D. Pegram, MD, director of the Breast Cancer Oncology Program, Stanford Women’s Cancer Center, co-director of Molecular Therapeutics Program, Stanford Medicine, discusses the phase III SOPHIA trial, which is exploring margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in the treatment of patients with HER2-positive breast cancer.
Read More
Denosumab Shows Survival Boost in Postmenopausal Women
December 11th 2015A follow-up benefits analysis of adding denosumab to aromatase inhibitor (AI) therapy shows the agent not only helps prevent fractures, it also reduces risk of recurrence and death in postmenopausal women with HR-positive breast cancer.
Read More
Adjuvant Capecitabine Boosts Survival Rates in HER2-Negative Breast Cancer
December 10th 2015A combination of capecitabine and adjuvant therapy dropped the risk of recurrence by 30% and prolonged survival by 40% for patients with residual breast cancer post-neoadjuvant chemotherapy and surgery, according to phase III data.
Read More
Breast Cancer Patients Referred for Genetic Testing Likely to Have Mutations Other Than BRCA1/2
January 21st 2015In an analysis of more than 17,000 patients with breast cancer, who are at risk for a genetic mutation, subjects were as likely to have a mutation in a gene other than BRCA1 and BRCA2 as they were to have these common mutations.
Read More
Gene Test Predicts Risk of Recurrence for DCIS Patients
December 13th 2014A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk. These results were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Women With TNBC May Benefit From Nutrition Intervention
December 13th 2014Findings from a long-term analysis of the Women’s Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake.
Read More
Everolimus Not for Frontline, But HR-Negative Subpopulation Data Offer Hope
December 13th 2014Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer.
Read More
Upfront Fulvestrant Improves OS Compared With Anastrozole in HR-Positive MBC
December 13th 2014Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer. These findings from the phase II FIRST trial were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Study Confirms Tamoxifen’s Sustained Power to Prevent Breast Cancer in Women at High Risk
December 12th 2014Five years of tamoxifen continues to offer protection against breast cancer— reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.
Read More
Chemo Provides No Benefit to Bisphosphonate Therapy in Older Patients With Breast Cancer
December 12th 2014Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine, according Gunter von Minckwitz, MD, who reported the results at the 2014 San Antonio Breast Cancer Symposium.
Read More
Ovarian Suppression Lowers Risk of Recurrence in Younger, Premenopausal Breast Cancer Patients
December 12th 2014Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or—to a lesser extent—tamoxifen, compared with standard tamoxifen alone.
Read More
Addition of Bevacizumab to Chemo Improves pCR Rates in Patients With Basal-Like Breast Cancer
December 12th 2014Adding bevacizumab to standard neoadjuvant chemotherapy significantly improved pathologic complete response rates in women with basal-like breast cancer compared with non-basal-like subtypes. These results from the CALGB 40603 trial were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Nab-Paclitaxel More Effective Than Paclitaxel in Neoadjuvant Breast Cancer Trial
December 11th 2014Nab-paclitaxel (Abraxane) was more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study. These results were presented at the 2014 San Antonio Breast Cancer Symposium.
Read More
Pembrolizumab Demonstrates Activity, Acceptable Safety in TNBC
December 11th 2014The PD-1 inhibitor pembrolizumab (Keytruda) has demonstrated promising clinical activity and an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer (TNBC).
Read More
Subset of Patients With MBC Benefits From PI3K Inhibitor Pictilisib
December 11th 2014Adding the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer (MBC) yielded a doubling in progression-free survival (PFS) in women with both estrogen receptor (ER)– and progesterone receptor (PR)–positive disease.
Read More